{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T12:27:46Z","timestamp":1747225666275},"reference-count":26,"publisher":"Consilium Medicum","issue":"7","license":[{"start":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T00:00:00Z","timestamp":1563148800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Terapevticheskii arkhiv"],"abstract":"<jats:p>Enzyme replacement therapy (ERT) is the standard for the treatment of Gaucher disease (GD). A lifelong intravenous administration of a recombinant analogue of human glucocerebrosidase compensates for the functional deficiency of its own enzyme. The use of ERT has changed the clinical phenotype of GD, a severe progressive disease has been turned into the status of an asymptomatic metabolic defect. At the same time, a reduced dosing ERT regimen applied in Gaucher patients who had achieved therapeutic goals has not yet been developed.<\/jats:p>","DOI":"10.26442\/00403660.2019.07.000327","type":"journal-article","created":{"date-parts":[[2019,8,4]],"date-time":"2019-08-04T22:18:01Z","timestamp":1564957081000},"page":"127-131","source":"Crossref","is-referenced-by-count":2,"title":["Enzyme replacement therapy in adult patients with type I Gaucher disease"],"prefix":"10.26442","volume":"91","author":[{"given":"R V","family":"Ponomarev","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E A","family":"Lukina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18344","published-online":{"date-parts":[[2019,7,15]]},"reference":[{"key":"ref1","unstructured":"\u041a\u0440\u0430\u0441\u043d\u043e\u043f\u043e\u043b\u044c\u0441\u043a\u0430\u044f \u041a.\u0414. \u041d\u0430\u0441\u043b\u0435\u0434\u0441\u0442\u0432\u0435\u043d\u043d\u044b\u0435 \u0431\u043e\u043b\u0435\u0437\u043d\u0438 \u043e\u0431\u043c\u0435\u043d\u0430 \u0432\u0435\u0449\u0435\u0441\u0442\u0432. \u041c.: \u041c\u0435\u0434\u0438\u0446\u0438\u043d\u0430, 2005."},{"key":"ref2","unstructured":"Zimran A, Elstein D. Lipid storage diseases. In: Lichtman M.A, Kipps T, Seligsohn U, Kaushansky K, Prchal J.T, ed. Williams Hematology. 8th ed; New York, NY: McGraw-Hill, 2010:1065-1071."},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Barak V, Acker M, Nisman B, Kalickman I, Abrahamov A, Zimran A, Yatziv S. Cytokines in Gaucher\u2019s disease. Eur Cytokine Netw. 1999;10:205-10.","DOI":"10.1006\/cyto.1998.0378"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00005-016-0421-y"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2018.02.006"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.177816"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-308890"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25074"},{"key":"ref9","unstructured":"De Duve C. The lysosomes: a novel group of cytoplasmic granules. J Physiol (Paris). 1957 Jan-Mar;49(1):113-5."},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Duve C. Exploring cells with a centrifuge. Science. 1975 Jul 18;189(4198):186-94.","DOI":"10.1126\/science.1138375"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Brady R.O, Kanfer J, Shapiro D. The metabolism of glucocerebrosides. i. purification and properties of a glucocerebroside - cleaving enzyme from spleen tissue. J Biol Chem. 1965 Jan;240:39-43.","DOI":"10.1016\/S0021-9258(18)97611-8"},{"key":"ref12","unstructured":"De Duve C. From cytases to lysosomes. Fed Proc. 1964 Sep-Oct;23:1045-9."},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Brady R.O, Tallman J.F, Johnson W.G, Gal A.E, Leahy W.E, Quirk J.M, Dekaban A.S. Replacement therapy for inherited enzyme deficiency: use of purified ceramidetrihexosidase in Fabry\u2019s disease. New Eng J Med. 1973;289:9-14.","DOI":"10.1056\/NEJM197307052890103"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Brady R.O, Pentchev P.G, Gal A.E, Hibbert S.R, Dekaban A.S. Replacement therapy for inherited enzyme deficiency: use of purified glucocerebrosidase in Gaucher\u2019s disease. New Eng J Med. 1974;291:989-93.","DOI":"10.1056\/NEJM197411072911901"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Doebber T.W, Wu M.S, Bugianesi R.L, Ponpipom M.M, Furbish F.S, Barranger J.A, Brady R.O, Shen T.Y. Enhanced macrophage uptake of synthetically glycosylated human placental b - glucocerebrosidase. J Biol Chem. 1982;257:2193-9.","DOI":"10.1016\/S0021-9258(18)34905-6"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Barton N.W, et al. Replacement therapy for inherited enzyme deficiency: macrophage - targeted glucocerebrosidase for Gaucher\u2019s disease. New Eng J Med. 1991;324:1464-70.","DOI":"10.1056\/NEJM199105233242104"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Anthony H. Futerman, Ari Zimran. Gaucher disease. Taylor & Francis Group. 2007;467.","DOI":"10.1201\/9781420005509"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2016.10.008"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Brady R.O, Barton N.W. Enzyme replacement therapy for Gaucher disease, critical investigations beyond demonstration of clinical efficacy. Biochem Med Metab Biol. 1994;52:1-9.","DOI":"10.1006\/bmmb.1994.1026"},{"key":"ref20","unstructured":"P\u00e9rez-Calvo J, Giraldo P, Pastores G.M, Fern\u00e1ndez-Gal\u00e1n M, Mart\u00edn-Nu\u00f1ez G, Pocov\u00ed M. Extended interval between enzyme therapy infusions for adult patients with Gaucher's disease type 1. J Postgrad Med. 2003 Apr-Jun;49(2):127-31."},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"De Fost M, Aerts J.M, Groener J.E, Maas M, Akkerman E.M, Wiersma M.G, Hollak C.E. Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trial. Haematologica. 2007 Feb;92(2):215-21.","DOI":"10.3324\/haematol.10635"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Elstein D, Abrahamov A, Hadas-Halpern I, Meyer A, Zimran A. Low - dose low - frequency imiglucerase as a starting regimen of enzyme replacement therapy for patients with type I Gaucher disease. QJM. 1998 Jul;91(7):483-8.","DOI":"10.1093\/qjmed\/91.7.483"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-308890"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2010.05.001"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2010.05.002"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2010.09.005"}],"container-title":["Terapevticheskii arkhiv"],"original-title":[],"link":[{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/33661\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/33661\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T21:43:35Z","timestamp":1634161415000},"score":1,"resource":{"primary":{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/view\/33661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,15]]},"references-count":26,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,7,15]]}},"URL":"https:\/\/doi.org\/10.26442\/00403660.2019.07.000327","relation":{},"ISSN":["2309-5342","0040-3660"],"issn-type":[{"value":"2309-5342","type":"electronic"},{"value":"0040-3660","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7,15]]}}}